Selective inhibition of prostaglandin E2 receptors EP2 and EP4 inhibits adhesion of human endometriotic epithelial and stromal cells through suppression of integrin-mediated mechanisms

Biology of Reproduction

Volumn 88, Issue 3, 2013, Pages

  Lee, JeHoon ^a   Banu, Sakhila K ^a   Burghardt, Robert C ^a   Starzinski Powitz, Anna ^b   Arosh, Joe A ^a  

^a TEXAS A AND M UNIVERSITY   (United States)

^b AK Neurobiologie und Biosensorik   (Germany)

Author keywords

Adhesion; Endometriosis; Human; Integrins; PGE2

Indexed keywords

ALPHA1 INTEGRIN; ALPHA2 INTEGRIN; ALPHA5 INTEGRIN; BETA ARRESTIN 1; BETA1 INTEGRIN; BETA3 INTEGRIN; BETA5 INTEGRIN; COLLAGEN TYPE 1; COLLAGEN TYPE 4; FIBRONECTIN; FOCAL ADHESION KINASE; FOCAL ADHESION KINASE 1; INTEGRIN; PROSTAGLANDIN E RECEPTOR 2; PROSTAGLANDIN E RECEPTOR 4; PROTEIN TYROSINE KINASE; SCLEROPROTEIN; VITRONECTIN;

ARTICLE; CELL ADHESION; ENDOMETRIUM CELL; ENZYME ACTIVITY; ENZYME INHIBITION; EPITHELIUM CELL; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; STROMA CELL; WESTERN BLOTTING;

ARRESTINS; CELL ADHESION; CELL LINE; DINOPROSTONE; ENDOMETRIOSIS; EXTRACELLULAR MATRIX; FEMALE; FOCAL ADHESION PROTEIN-TYROSINE KINASES; HUMANS; INTEGRINS; RECEPTORS, PROSTAGLANDIN E, EP2 SUBTYPE; RECEPTORS, PROSTAGLANDIN E, EP4 SUBTYPE; SRC-FAMILY KINASES; TALIN;

EID: 84877044776     PISSN: 00063363     EISSN: 15297268     Source Type: Journal    
DOI: 10.1095/biolreprod.112.100883     Document Type: Article

References (75)

1. Bulun SE. Endometriosis. N Engl J Med 2009; 360:268-279.
2. Giudice LC, Kao LC. Endometriosis. Lancet 2004; 364:1789-1799.
3. De Leon FD, Vijayakumar R, Brown M, Rao CV, Yussman MA, Schultz G. Peritoneal fluid volume, estrogen, progesterone, prostaglandin, and epidermal growth factor concentrations in patients with and without endometriosis. Obstet Gynecol 1986; 68:189-194.
4. Wu MH, Shoji Y, Chuang PC, Tsai SJ. Endometriosis: disease pathophysiology and the role of prostaglandins. Expert Rev Mol Med 2007; 9:1-20.
5. Smith WL, Dewitt DL. Prostaglandin endoperoxide H synthases-1 and-2. Adv Immunol 1996; 62:167-215.
6. Tai HH, Ensor CM, Tong M, Zhou H, Yan F. Prostaglandin catabolizing enzymes. Prostaglandins Other Lipid Mediat 2002; 68-69:483-493.
7. Schuster VL. Molecular mechanisms of prostaglandin transport. Annu Rev Physiol 1998; 60:221-242.
8. Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev 1999; 79:1193-1226.
9. Coleman RA, Smith WL, Narumiya S. International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev 1994; 46:205-229.
10. Cha YI, DuBois RN. NSAIDs and cancer prevention: targets downstream of COX-2. Annu Rev Med 2007; 58:239-252.
11. Fujino H, Regan JW. Prostaglandin F(2alpha) stimulation of cyclooxygenase-2 promoter activity by the FP(B) prostanoid receptor. Eur J Pharmacol 2003; 465:39-41.
12. Jabbour HN, Sales KJ. Prostaglandin receptor signalling and function in human endometrial pathology. Trends Endocrinol Metab 2004; 15:398-404.
13. Buchanan FG, Gorden DL, Matta P, Shi Q, Matrisian LM, DuBois RN. Role of beta-arrestin 1 in the metastatic progression of colorectal cancer. Proc Natl Acad Sci U S A 2006; 103:1492-1497.
14. Castellone MD, Teramoto H, Williams BO, Druey KM, Gutkind JS. Prostaglandin E2 promotes colon cancer cell growth through a Gs-axinbeta-catenin signaling axis. Science 2005; 310:1504-1510.
15. Banu SK, Lee J, Speights VO Jr, Starzinski-Powitz A, Arosh JA. Selective inhibition of prostaglandin E2 receptors EP2 and EP4 induces apoptosis of human endometriotic cells through suppression of ERK1/2, AKT, NFkB and b-catenin pathways and activation of intrinsic apoptotic mechanisms. Mol Endocrinol 2009; 23:1291-1305.
16. Wang D, Dubois RN. Eicosanoids and cancer. Nat Rev Cancer 10:181-193.
17. Wang D, Dubois RN. Prostaglandins and cancer. Gut 2006; 55:115-122.
18. Banu SK, Lee J, Speights VO, Starzinski-Powitz A, Arosh JA. Cyclooxygenase-2 regulates survival, migration and invasion of human endometriotic cells through multiple mechanisms. Endocrinology 2008; 149:1180-1189.
19. Chishima F, Hayakawa S, Sugita K, Kinukawa N, Aleemuzzaman S, Nemoto N, Yamamoto T, Honda M. Increased expression of cyclooxygenase-2 in local lesions of endometriosis patients. Am J Reprod Immunol 2002; 48:50-56.
20. Ota H, Igarashi S, Sasaki M, Tanaka T. Distribution of cyclooxygenase-2 in eutopic and ectopic endometrium in endometriosis and adenomyosis. Hum Reprod 2001; 16:561-566.
21. Cobellis L, Razzi S, De Simone S, Sartini A, Fava A, Danero S, Gioffre W, Mazzini M, Petraglia F. The treatment with a COX-2 specific inhibitor is effective in the management of pain related to endometriosis. Eur J Obstet Gynecol Reprod Biol 2004; 116:100-102.
22. Kim YA, Kim MR, Lee JH, Kim JY, Hwang KJ, Kim HS, Lee ES. Gonadotropin-releasing hormone agonist reduces aromatase cytochrome P450 and cyclooxygenase-2 in ovarian endometrioma and eutopic endometrium of patients with endometriosis. Gynecol Obstet Invest 2009; 68:73-81.
23. Olivares C, Bilotas M, Buquet R, Borghi M, Sueldo C, Tesone M, Meresman G. Effects of a selective cyclooxygenase-2 inhibitor on endometrial epithelial cells from patients with endometriosis. Hum Reprod 2008; 23:2701-2708.
24. Matsuzaki S, Canis M, Darcha C, Dallel R, Okamura K, Mage G. Cyclooxygenase-2 selective inhibitor prevents implantation of eutopic endometrium to ectopic sites in rats. Fertil Steril 2004; 82:1609-1615.
25. Laschke MW, Elitzsch A, Scheuer C, Vollmar B, Menger MD. Selective cyclo-oxygenase-2 inhibition induces regression of autologous endometrial grafts by down-regulation of vascular endothelial growth factormediated angiogenesis and stimulation of caspase-3-dependent apoptosis. Fertil Steril 2007; 87:163-171.
26. Lee J, Banu SK, Rodriguez R, Starzinski-Powitz A, Arosh JA. Selective blockade of prostaglandin E2 receptors EP2 and EP4 signaling inhibits proliferation of human endometriotic epithelial cells and stromal cells through distinct cell cycle arrest. Fertil Steril 2010; 93:2498-2506.
27. Lee J, Banu SK, Subbarao T, Starzinski-Powitz A, Arosh JA. Selective inhibition of prostaglandin E2 receptors EP2 and EP4 inhibits invasion of human immortalized endometriotic epithelial and stromal cells through suppression of metalloproteinases. Mol Cell Endocrinol 2011; 332:306-313.
28. Osteen KG, Yeaman GR, Bruner-Tran KL. Matrix metalloproteinases and endometriosis. Semin Reprod Med 2003; 21:155-164.
29. Pitsos M, Kanakas N. The role of matrix metalloproteinases in the pathogenesis of endometriosis. Reprod Sci 2009; 16:717-726.
30. Zhou HE, Nothnick WB. The relevancy of the matrix metalloproteinase system to the pathophysiology of endometriosis. Front Biosci 2005; 10:569-575.
31. Klemmt PA, Carver JG, Koninckx P, McVeigh EJ, Mardon HJ. Endometrial cells from women with endometriosis have increased adhesion and proliferative capacity in response to extracellular matrix components: towards a mechanistic model for endometriosis progression. Hum Reprod 2007; 22:3139-3147.
32. Regidor PA, Vogel C, Regidor M, Schindler AE, Winterhager E. Expression pattern of integrin adhesion molecules in endometriosis and human endometrium. Hum Reprod Update 1998; 4:710-718.
33. Witz CA, Montoya-Rodriguez IA, Cho S, Centonze VE, Bonewald LF, Schenken RS. Composition of the extracellular matrix of the peritoneum. J Soc Gynecol Investig 2001; 8:299-304.
34. Witz CA, Takahashi A, Montoya-Rodriguez IA, Cho S, Schenken RS. Expression of the alpha2beta1 and alpha3beta1 integrins at the surface of mesothelial cells: a potential attachment site of endometrial cells. Fertil Steril 2000; 74:579-584.
35. Askari JA, Buckley PA, Mould AP, Humphries MJ. Linking integrin conformation to function. J Cell Sci 2009; 122:165-170.
36. Harburger DS, Calderwood DA. Integrin signalling at a glance. J Cell Sci 2009; 122:159-163.
37. Humphries JD, Byron A, Humphries MJ. Integrin ligands at a glance. J Cell Sci 2006; 119:3901-3903.
38. Legate KR, Fassler R. Mechanisms that regulate adaptor binding to betaintegrin cytoplasmic tails. J Cell Sci 2009; 122:187-198.
39. Heyman L, Kellouche S, Fernandes J, Dutoit S, Poulain L, Carreiras F. Vitronectin and its receptors partly mediate adhesion of ovarian cancer cells to peritoneal mesothelium in vitro. Tumour Biol 2008; 29:231-244.
40. Kenny HA, Krausz T, Yamada SD, Lengyel E. Use of a novel 3D culture model to elucidate the role of mesothelial cells, fibroblasts and extracellular matrices on adhesion and invasion of ovarian cancer cells to the omentum. Int J Cancer 2007; 121:1463-1472.
41. Lessan K, Aguiar DJ, Oegema T, Siebenson L, Skubitz AP. CD44 and beta1 integrin mediate ovarian carcinoma cell adhesion to peritoneal mesothelial cells. Am J Pathol 1999; 154:1525-1537.
42. Strobel T, Cannistra SA. Beta1-integrins partly mediate binding of ovarian cancer cells to peritoneal mesothelium in vitro. Gynecol Oncol 1999; 73:362-367.
43. Witz CA, Thomas MR, Montoya-Rodriguez IA, Nair AS, Centonze VE, Schenken RS. Short-term culture of peritoneum explants confirms attachment of endometrium to intact peritoneal mesothelium. Fertil Steril 2001; 75:385-390.
44. Attur MG, Dave MN, Clancy RM, Patel IR, Abramson SB, Amin AR. Functional genomic analysis in arthritis-affected cartilage: yin-yang regulation of inflammatory mediators by alpha 5 beta 1 and alpha V beta 3 integrins. J Immunol 2000; 164:2684-2691.
45. Dormond O, Bezzi M, Mariotti A, Ruegg C. Prostaglandin E2 promotes integrin alpha Vbeta 3-dependent endothelial cell adhesion, rac-activation, and spreading through cAMP/PKA-dependent signaling. J Biol Chem 2002; 277:45838-45846.
46. Kajimoto M, Ichiyama T, Ueno Y, Shiraishi M, Hasegawa M, Furukawa S. Enhancement of activated beta1-integrin expression by prostaglandin E2 via EP receptors in isolated human coronary arterial endothelial cells: implication for the treatment of Kawasaki disease. Inflamm Res 2009; 58:224-228.
47. Waldner C, Schror K, Heering P. COX-2 dependent PGE(2) downregulates alpha(v) integrin expression via the EP(3) receptor in cultured mesangial cells. J Clin Pathol 2004; 57:553-555.
48. Zeitvogel A, Baumann R, Starzinski-Powitz A. Identification of an invasive, N-cadherin-expressing epithelial cell type in endometriosis using a new cell culture model. Am J Pathol 2001; 159:1839-1852.
49. Banu SK, Lee J, Satterfield MC, Spencer TE, Bazer FW, Arosh JA. Molecular cloning and characterization of prostaglandin transporter in ovine endometrium: role of mitogen activated protein kinase pathways in release of prostaglandin F2 alpha. Endocrinology 2008; 149:219-231.
50. Wu Y, Starzinski-Powitz A, Guo SW. Trichostatin A, a histone deacetylase inhibitor, attenuates invasiveness and reactivates E-cadherin expression in immortalized endometriotic cells. Reprod Sci 2007; 14:374-382.
51. Banu SK, Starzinski-Powitz A, Speights VO, Burghardt RC, Arosh JA. Induction of peritoneal endometriosis in nude mice using human immortalized endometriosis epithelial and stromal cells: a potential experimental tool to study molecular pathogenesis of endometriosis in human. Fertil Steril 2009; 91:2199-2209.
52. Banu SK, Lee J, Starzinski-Powitz A, Arosh JA. Gene expression profiles and functional characterization of human immortalized endometriotic epithelial and stromal cells. Fertil Steril 2008; 90:972-987.
53. Woodward DF, Pepperl DJ, Burkey TH, Regan JW. 6-Isopropoxy-9-oxoxanthene-2-carboxylic acid (AH 6809), a human EP2 receptor antagonist. Biochem Pharmacol 1995; 50:1731-1733.
54. Crider JY, Griffin BW, Sharif NA. Endogenous EP4 prostaglandin receptors coupled positively to adenylyl cyclase in Chinese hamster ovary cells: pharmacological characterization. Prostaglandins Leukot Essent Fatty Acids 2000; 62:21-26.
55. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72:248-254.
56. Legate KR, Wickstrom SA, Fassler R. Genetic and cell biological analysis of integrin outside-in signaling. Genes Dev 2009; 23:397-418.
57. Moser M, Legate KR, Zent R, Fassler R. The tail of integrins, talin, and kindlins. Science 2009; 324:895-899.
58. Vicente-Manzanares M, Choi CK, Horwitz AR. Integrins in cell migration-the actin connection. J Cell Sci 2009; 122:199-206.
59. Fong YC, Liu SC, Huang CY, Li TM, Hsu SF, Kao ST, Tsai FJ, Chen WC, Chen CY, Tang CH. Osteopontin increases lung cancer cells migration via activation of the alphavbeta3 integrin/FAK/Akt and NF-kappaB-dependent pathway. Lung Cancer 2009; 64:263-270.
60. Thamilselvan V, Craig DH, Basson MD. FAK association with multiple signal proteins mediates pressure-induced colon cancer cell adhesion via a Src-dependent PI3K/Akt pathway. FASEB J 2007; 21:1730-1741.
61. Webb DJ, Donais K, Whitmore LA, Thomas SM, Turner CE, Parsons JT, Horwitz AF. FAK-Src signalling through paxillin, ERK and MLCK regulates adhesion disassembly. Nat Cell Biol 2004; 6:154-161.
62. Giannelli G, Sgarra C, Di Naro E, Lavopa C, Angelotti U, Tartagni M, Simone O, Trerotoli P, Antonaci S, Loverro G. Endometriosis is characterized by an impaired localization of laminin-5 and alpha3beta1 integrin receptor. Int J Gynecol Cancer 2007; 17:242-247.
63. Koks CA, Groothuis PG, Dunselman GA, de Goeij AF, Evers JL. Adhesion of menstrual endometrium to extracellular matrix: the possible role of integrin alpha(6)beta(1) and laminin interaction. Mol Hum Reprod 2000; 6:170-177.
64. Lessey BA, Castelbaum AJ. Integrins and implantation in the human. Rev Endocr Metab Disord 2002; 3:107-117.
65. Lessey BA, Castelbaum AJ, Wolf L, Greene W, Paulson M, Meyer WR, Fritz MA. Use of integrins to date the endometrium. Fertil Steril 2000; 73:779-787.
66. Rai V, Hopkisson J, Kennedy S, Bergqvist A, Barlow DH, Mardon HJ. Integrins alpha 3 and alpha 6 are differentially expressed in endometrium and endometriosis. J Pathol 1996; 180:181-187.
67. Sillem M, Prifti S, Monga B, Arslic T, Runnebaum B. Integrin-mediated adhesion of uterine endometrial cells from endometriosis patients to extracellular matrix proteins is enhanced by tumor necrosis factor alpha (TNF alpha) and interleukin-1 (IL-1). Eur J Obstet Gynecol Reprod Biol 1999; 87:123-127.
68. Lerea KM, Venjara AY, Olson SC, Kelly MR. Threonine phosphorylation of integrin beta3 in calyculin A-treated platelets is selectively sensitive to 50-iodotubercidin. Biochim Biophys Acta 2007; 1773:185-191.
69. Kirk RI, Sanderson MR, Lerea KM. Threonine phosphorylation of the beta 3 integrin cytoplasmic tail, at a site recognized by PDK1 and Akt/PKB in vitro, regulates Shc binding. J Biol Chem 2000; 275:30901-30906.
70. Wegener KL, Partridge AW, Han J, Pickford AR, Liddington RC, Ginsberg MH, Campbell ID. Structural basis of integrin activation by talin. Cell 2007; 128:171-182.
71. Law DA, DeGuzman FR, Heiser P, Ministri-Madrid K, Killeen N, Phillips DR. Integrin cytoplasmic tyrosine motif is required for outside-in alphaIIbbeta3 signalling and platelet function. Nature 1999; 401:808-811.
72. Sakai T, Zhang Q, Fassler R, Mosher DF. Modulation of beta1A integrin functions by tyrosine residues in the beta1 cytoplasmic domain. J Cell Biol 1998; 141:527-538.
73. Buchanan FG, Wang D, Bargiacchi F, DuBois RN. Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem 2003; 278:35451-35457.
74. Pierce KL, Lefkowitz RJ. Classical and new roles of beta-arrestins in the regulation of G-protein-coupled receptors. Nat Rev Neurosci 2001; 2:727-733.
75. Luttrell LM, Ferguson SS, Daaka Y, Miller WE, Maudsley S, Della Rocca GJ, Lin F, Kawakatsu H, Owada K, Luttrell DK, Caron MG, Lefkowitz RJ. Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes. Science 1999; 283:655-661.